Findings from NeoCOAST, a phase II trial, suggest that in early-stage operable non–small cell lung cancer, combination strategies may boost the PD-L1 inhibitor durvalumab's neoadjuvant efficacy.

©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.